Get the latest news, insights, and market updates on TMDX (TransMedics Group, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
A Look At TransMedics Group (TMDX) Valuation After Full FDA Approval For Next Generation OCS Heart Trial
TransMedics Group (TMDX) is back in focus after the U.S. Food and Drug Administration granted full approval of its Investigational Device Exemption for the Next Generation OCS ENHANCE Heart clinical trial. See our latest analysis for TransMedics Group. The latest FDA approval comes after a reshuffle in TransMedics Group's commercial and legal leadership and ahead of upcoming healthcare conference appearances. The share price at US$133.82 and a 1-year total shareholder return of 68.5% point to... Feb 18, 2026 - $TMDX
FDA Greenlights TransMedics ENHANCE Heart Trial Shaping Growth Prospects
TransMedics Group (NasdaqGM:TMDX) received full FDA approval for its Next-Generation OCS ENHANCE Heart trial. The decision clears a key regulatory hurdle for the company’s heart-focused organ care system program. The approval relates specifically to the next generation of TransMedics’ Organ Care System platform for heart transplants. TransMedics Group focuses on organ transplant technologies, aiming to support the preservation and assessment of organs outside the human body. This latest FDA... Feb 18, 2026 - $TMDX
What Catalysts Are Reframing The TransMedics Group (TMDX) Narrative Now
Why the TransMedics price target is holding steady Analysts covering TransMedics Group are keeping their fair value estimate anchored at US$144.20, even after the recent competitor clearance and share price volatility. The small uptick in the discount rate and unchanged revenue growth assumptions reflect a view that sentiment has shifted more than the underlying story, with the core growth framework left largely intact. If you want to stay in front of any further tweaks to that fair value and... Feb 18, 2026 - $TMDX
The Bull Case For TransMedics Group (TMDX) Could Change Following Full FDA Approval Of ENHANCE Heart Trial
TransMedics Group recently received full FDA approval for its Next-Generation OCS ENHANCE Heart Investigational Device Exemption trial, advancing efforts to validate prolonged heart perfusion and superiority over static cold storage in donation-after-brain-death cases. This step, alongside earlier FDA clearance for its next-generation lung trial, highlights TransMedics’ push to extend its Organ Care System platform across more complex clinical settings. We’ll now examine how full FDA... Feb 18, 2026 - $TMDX
6 Stock Ideas for the Next 5 Years
Listen in as Motley Fool co-founder Tom Gardner and Chief Investment Officer Andy Cross talk about stocks! Feb 17, 2026 - $TMDX
TransMedics to Present at Upcoming March Investor Conferences
TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced the company will be participating in two upcoming investor conferences. TransMedics management is scheduled to participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference in Boston on Monday, March 2, 2026, at 1:50 p.m. EST and virtually at the Oppenheimer 36th Annual He Feb 17, 2026 - $TMDX
DexCom (DXCM) Q4 Earnings and Revenues Top Estimates
DexCom (DXCM) delivered earnings and revenue surprises of +4.62% and +0.64%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock? Feb 12, 2026 - $TMDX
TransMedics to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026
TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the fourth quarter and full year 2025 after market close on Tuesday, February 24, 2026. The TransMedics management team will host a corresponding conference call beginning at 4:30 p.m. ET / 1:30 p.m. PT. Feb 10, 2026 - $TMDX
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple